• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive

Dec 12, 2025

Select the category

  • All categories
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1
  • Covid-19

Select the year

  • All years
  • 2024
  • 2023
  • 2022
Clear Filters
U

Scancell to present three posters at the Seventh International Cancer Immunotherapy Conference

September 14, 2023

Scancell Appoints Dr Mandeep Sehmi as Head of Business Development

September 7, 2023

Scancell Appoints Sath Nirmalananthan as Chief Financial Officer

August 29, 2023

What do cancer-specific T cells ‘see’?

August 14, 2023

Modi-1 trial open for expansion in combination with checkpoint inhibitors

July 31, 2023

Extension of exercise period for CEO share options

July 13, 2023

Pipeline strategy and business update

July 10, 2023

Annual Meeting of the American Society of Clinical Oncology (ASCO), 2 – 6 June 2023 in Chicago, Illinois, USA

June 3, 2023

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting

June 2, 2023

SARS-Cov-2 Spike RBD and Nucleocapsid Encoding DNA Vaccine Elicits T cell and Neutralising Antibody Responses that Cross React with Variants

May 26, 2023

Annual Report 30th April 2023

April 30, 2023

Issue of share options to Non-Executive Directors

April 21, 2023
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 5
No results found.

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    About Us
    Leadership Team
    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy